Información del producto
- 1-[(3α,5β)-3-Hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl]-1H-pyrazole-4-carbonitrile
- Zuranolone
- 1H-Pyrazole-4-carbonitrile, 1-[(3α,5β)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl]-
- SAGE 217
- 1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile
- 1H-Pyrazole-4-carbonitrile, 1-[(3α,5β)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl]-
- SGE 797
SAGE-217 is a novel antidepressant drug that has been shown to be effective in the treatment of depression. The drug is orally administered and is rapidly absorbed, with peak plasma concentrations occurring within one hour. It binds to GABA receptors and blocks the binding of the neurotransmitter gamma-aminobutyric acid (GABA) to its receptor, which reduces brain activity and has an anti-anxiety effect. SAGE-217 may also have other effects on neurotransmitters, such as serotonin or dopamine, but this remains unclear.
Propiedades químicas
Consulta técnica sobre: 3D-HQC05140 SAGE-217
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.